| The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerBRN2 Is an AR-Suppressed Driver of NEPC JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ... Cancer discovery 7 (1), 54-71, 2017 | 283 | 2017 |
| High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell GrowthHTS for Selective … K Iljin, K Ketola, P Vainio, P Halonen, P Kohonen, V Fey, RC Grafström, ... Clinical Cancer Research 15 (19), 6070-6078, 2009 | 205 | 2009 |
| A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative … RE Kast, JA Boockvar, A Brüning, F Cappello, WW Chang, B Cvek, ... Oncotarget 4 (4), 502, 2013 | 188 | 2013 |
| Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress K Ketola, M Hilvo, T Hyötyläinen, A Vuoristo, AL Ruskeepää, M Orešič, ... British journal of cancer 106 (1), 99-106, 2012 | 182 | 2012 |
| Using online game-based platforms to improve student performance and engagement in histology teaching S Felszeghy, S Pasonen-Seppänen, A Koskela, P Nieminen, K Härkönen, ... BMC medical education 19, 1-11, 2019 | 168 | 2019 |
| Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer P Vainio, S Gupta, K Ketola, T Mirtti, JP Mpindi, P Kohonen, V Fey, ... The American journal of pathology 178 (2), 525-536, 2011 | 157 | 2011 |
| High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion L Lehtinen, K Ketola, R Mäkelä, JP Mpindi, M Viitala, O Kallioniemi, K Iljin Oncotarget 4 (1), 48, 2013 | 115 | 2013 |
| PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A–mediated inactivation in human malignant glioma P Puustinen, MR Junttila, S Vanhatupa, AA Sablina, ME Hector, ... Cancer research 69 (7), 2870-2877, 2009 | 102 | 2009 |
| Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells K Ketola, P Vainio, V Fey, O Kallioniemi, K Iljin Molecular cancer therapeutics 9 (12), 3175-3185, 2010 | 90 | 2010 |
| High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer P Vainio, JP Mpindi, P Kohonen, V Fey, T Mirtti, KA Alanen, M Perälä, ... PloS one 7 (6), e39801, 2012 | 89 | 2012 |
| The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017; 7: 54–71. doi … JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ... This works provides a mechanistic model for neuroendocrine differentiation …, 0 | 73 | |
| Regulation of tumor cell plasticity by the androgen receptor in prostate cancer JL Bishop, A Davies, K Ketola, A Zoubeidi Endocr Relat Cancer 22 (3), R165-R182, 2015 | 55 | 2015 |
| Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ... Nature communications 12 (1), 5307, 2021 | 32 | 2021 |
| Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway InhibitionTargeting PCS1 by FOXM1 Pathway Inhibition K Ketola, RSN Munuganti, A Davies, KM Nip, JL Bishop, A Zoubeidi Clinical Cancer Research 23 (22), 6923-6933, 2017 | 30 | 2017 |
| Targeting Lyn regulates Snail family shuttling and inhibits metastasis D Thaper, S Vahid, KM Nip, I Moskalev, X Shan, S Frees, ME Roberts, ... Oncogene 36 (28), 3964-3975, 2017 | 28 | 2017 |
| Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells K Ketola, O Kallioniemi, K Iljin PloS one 7 (12), e51470, 2012 | 27 | 2012 |
| The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells PR Braadland, H Ramberg, HH Grytli, A Urbanucci, HK Nielsen, ... Molecular Cancer Research 17 (11), 2154-2168, 2019 | 24 | 2019 |
| CD44s assembles hyaluronan coat on filopodia and extracellular vesicles and induces tumorigenicity of MKN74 gastric carcinoma cells K Härkönen, S Oikari, H Kyykallio, J Capra, S Hakkola, K Ketola, ... Cells 8 (3), 276, 2019 | 22 | 2019 |
| Axon guidance-related factor FLRT3 regulates VEGF-signaling and endothelial cell function S Jauhiainen, JP Laakkonen, K Ketola, PI Toivanen, T Nieminen, ... Frontiers in physiology 10, 224, 2019 | 18 | 2019 |
| High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer K Ketola, M Viitala, P Kohonen, V Fey, Z Culig, O Kallioniemi, K Iljin Journal of molecular biochemistry 5 (1), 12, 2016 | 15 | 2016 |
Amina ZoubeidiUniversity of British ColumbiaVerified email at prostatecentre.com
